Dec 29, 2025
Polycystic Kidney Disease: Understanding the Genetics and Real-Life Management
The FDA doesn't rate biosimilars like generics-it evaluates them through a rigorous scientific process to prove they're highly similar and safe. Learn how biosimilars are approved, why they're different from generics, and what the Purple Book means for patients.